CYTOGEN ANNOUNCES INTERIM DATA FROM QUADRAMET STUDY

Cytogen has announced interim results from a Phase I clinical trial of Quadramet (samarium Sm-153 lexidronam injection) in combination with bortezomib in patients whose multiple myeloma has relapsed following prior treatment.

Data from the ongoing study indicate that the combination regimen, known as Velsam, was well-tolerated at doses studied to date and demonstrated anti-tumor activity, with fifty percent of patients experiencing a response or achieving stable disease.